866-997-4948(US-Canada Toll Free)

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 53 Pages

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Influenza A Virus, H7N9 Subtype Infections Overview 7
Therapeutics Development 8
Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Overview 8
Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis 9
Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Development by Companies 10
Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 11
Influenza A Virus, H7N9 Subtype Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Influenza A Virus, H7N9 Subtype Infections - Products under Development by Companies 14
Influenza A Virus, H7N9 Subtype Infections - Products under Investigation by Universities/Institutes 15
Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development 16
EpiVax Inc 16
Fabentech 17
Genentech Inc 18
GlaxoSmithKline Plc 19
Medigen Vaccine Biologics Corp 20
NanoViricides Inc 21
Visterra Inc 22
Vivaldi Biosciences Inc 23
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AT-501 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
FBF-002 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSK-3206640A - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GSK-3206641A - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
influenza [strain A/H7N9] vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
influenza [strain A/H7N9] vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Monoclonal Antibody to Inhibit Hemagglutinin for Influenzavirus A Infections - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
NVINF-1 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NVINF-2 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
VIS-410 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H2 2016 16
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Fabentech, H2 2016 17
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H2 2016 18
Influenza A Virus, H7N9 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 19
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2016 20
Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H2 2016 21
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H2 2016 22
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32

List of Figures
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Targets, H2 2016 25
Number of Products by Stage and Targets, H2 2016 25
Number of Products by Mechanism of Actions, H2 2016 27
Number of Products by Stage and Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *